XNAS
XWEL
Market cap7mUSD
Oct 08, Last price
0.92USD
1D
1.88%
1Q
-3.55%
IPO
-99.95%
Name
XWELL Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
XpresSpa Group, Inc. is a health and wellness enterprise primarily serving air travelers within airport environments. The company operates through three main divisions: XpresSpa, XpresTest, and Treat. Its XpresSpa segment provides a range of personal care services, including therapeutic massages, nail treatments, and skin care, alongside the sale of spa and travel-related merchandise. Beyond relaxation, the company's wellness centers, under the XpresTest banner, offer vital health services. These include screening and rapid diagnostic testing for various infectious diseases such as COVID-19, influenza (including A&B strains), and RSV, as well as seasonal flu vaccinations and other medical diagnostic tests. These offerings are made accessible to the traveling public via a streamlined digital platform and specialized retail outlets. As of December 31, 2021, XpresSpa Group managed a network of 52 spa and clinic locations situated in 24 airports across the United States, the Netherlands, and the United Arab Emirates. Formerly known as FORM Holdings Corp., the company adopted its current name in January 2018 and is headquartered in New York, New York.
Key people
Douglas Satzman
Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer, Director · since 2019
Scott R. Milford
Chief People Officer · since 2019
Michael Lebowitz
Director · since 2020
Independent Director · since 2017
Donald E. Stout
Independent Director · since 2012
Legal address
c/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
WILMINGTON, DE 19808
US
Headquarters
254 W 31st Street; 11th Floor
New York, NY 10001
US
New York, NY 10001
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||